Pineal DMT Production: What We Know from Rick Strassman to 2025 Studies

Rick Strassman and the Spirit Molecule Hypothesis

The modern scientific investigation of pineal DMT production begins with Rick Strassman, a clinical psychiatrist at the University of New Mexico School of Medicine. Between 1990 and 1995, Strassman conducted the first FDA-approved research with DMT (N,N-dimethyltryptamine) since the compound's prohibition under the 1970 Controlled Substances Act. Over five years, he administered roughly 400 doses of IV DMT to approximately 60 volunteer subjects, meticulously documenting their experiences.

The experiences Strassman's subjects reported were consistent and extraordinary. Within 30-60 seconds of injection, volunteers described leaving their bodies, entering spaces of brilliant light or complex geometric architecture, encountering apparently autonomous beings, and experiencing states of consciousness they rated as the most profound of their lives. The consistency of these reports across diverse individuals, combined with the precision and speed of DMT's effects, convinced Strassman that the compound had a deeper biological significance than recreational pharmacology suggested.

In his 2001 book "DMT: The Spirit Molecule," Strassman articulated the hypothesis that made his work famous: the pineal gland naturally produces DMT, releasing it during four key biological transitions. First, at birth, where a DMT release might contribute to the transition from pre-natal to post-natal consciousness. Second, during REM sleep, where endogenous DMT might generate the vivid imagery and narrative complexity of dreams. Third, during near-death experiences, where a massive DMT release could produce the tunnel of light, life review, and transcendent experiences reported by NDE survivors. Fourth, during spontaneous mystical or peak experiences, where pineal DMT release could produce the unity consciousness, ego dissolution, and sense of cosmic significance these experiences characteristically involve.

Strassman's choice of the pineal gland as the proposed production site was not arbitrary. He identified several features that made it the strongest candidate: the gland contains the necessary biosynthetic enzymes (INMT), it sits outside the blood-brain barrier (allowing produced DMT to enter both blood and cerebrospinal fluid), it is already known to produce the consciousness-modifying hormone melatonin, and its unique position as the only unpaired brain structure gives it a special status in both neuroscience and esoteric traditions (Descartes' "seat of the soul," the Hindu ajna chakra, the biblical "single eye").

The Biochemistry of Pineal DMT Synthesis

Understanding the biochemical pathway for DMT synthesis is essential for evaluating whether the pineal gland can actually produce it. The pathway is straightforward in principle, requiring only two enzymatic steps from a common dietary amino acid.

Step one: the amino acid tryptophan, abundant in protein-rich foods (turkey, eggs, cheese, nuts, seeds), is converted to tryptamine by the enzyme aromatic amino acid decarboxylase (AADC). AADC is widely distributed throughout the body and brain, making tryptamine readily available as a DMT precursor.

Step two: tryptamine is converted to N,N-DMT by the enzyme indolethylamine-N-methyltransferase (INMT). INMT performs two sequential N-methylation reactions, first producing N-methyltryptamine (NMT), then converting NMT to N,N-DMT by adding a second methyl group. The methyl groups are donated by S-adenosylmethionine (SAMe), a common cellular methyl donor.

The critical question is where INMT is located in the body. If it is present in the pineal gland, pineal DMT production is biochemically possible. Multiple studies have confirmed INMT expression in the pineal gland, as well as in the lungs, liver, kidneys, and certain brain regions. The pineal gland's INMT expression, combined with its access to tryptamine precursors and methyl donors, establishes the biochemical capacity for pineal DMT synthesis.

The lungs' INMT expression is particularly interesting in light of breathwork traditions. Practices like holotropic breathing, Wim Hof method, and yogic pranayama produce altered states of consciousness that share some phenomenological features with DMT experiences (visual phenomena, altered time perception, emotional release). If the lungs produce DMT, intense breathing practices might increase pulmonary DMT synthesis through increased enzymatic activity, providing a physiological mechanism for breathwork-induced altered states.

5-MeO-DMT, the related compound discussed in our comprehensive comparison, requires an additional enzymatic step: 5-hydroxylation of DMT by the enzyme CYP2D6, followed by O-methylation by hydroxyindole-O-methyltransferase (HIOMT). HIOMT is the same enzyme that converts N-acetylserotonin to melatonin in the pineal gland, creating a direct biochemical link between melatonin and 5-MeO-DMT synthesis pathways.

The University of Michigan Breakthrough (2013)

For twelve years after Strassman published his hypothesis, pineal DMT production remained theoretically plausible but experimentally unconfirmed. The breakthrough came in 2013 from Jimo Borjigin's laboratory at the University of Michigan.

Using microdialysis, a technique that inserts a tiny probe into living brain tissue and continuously samples the chemical environment, Borjigin's team detected DMT in the brains of living rats. This was the first confirmation that DMT is present in living mammalian brain tissue, not just in post-mortem samples where it could theoretically form as a decomposition artefact.

The study also investigated what happens to DMT levels during cardiac arrest, directly testing Strassman's near-death hypothesis. When the researchers induced cardiac arrest in the rats, DMT levels in the brain increased significantly. This finding provided the first experimental support for the idea that dying brains produce elevated DMT, potentially explaining the vivid, transcendent experiences reported by near-death experience survivors.

The Michigan study had limitations. It measured DMT in whole brain tissue rather than specifically in the pineal gland. It used rats, and the applicability to human neurobiology, while likely given the conserved nature of tryptamine biochemistry across mammals, was not directly established. And the DMT concentrations detected, while elevated during cardiac arrest, were lower than those achieved during Strassman's exogenous DMT experiments, raising questions about whether endogenous levels could reach experientially significant concentrations.

Dean et al. 2019: Pineal Tissue Confirmation and Cardiac Arrest Elevation

The most significant study to date on endogenous DMT production was published in 2019 by Jon Dean, Tijiang Liu, Sean Huff, and colleagues in Scientific Reports (a Nature Publishing Group journal). This study addressed several limitations of the earlier Michigan work and produced three findings that substantially advanced the field.

First, the study confirmed DMT biosynthesis in living rat brains using improved microdialysis techniques with higher sensitivity than the 2013 study. The detection methods were rigorous, using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) to identify DMT unambiguously among the thousands of chemical species present in brain tissue.

Second, and most significantly for the Strassman hypothesis, the study detected DMT specifically in rat pineal gland tissue. This was the first direct evidence that the pineal gland contains DMT, moving the hypothesis from "the pineal has the enzymes to make DMT" to "the pineal actually contains DMT." The study also found DMT in the cerebral cortex, confirming that the pineal is not the only brain region involved in DMT production or accumulation.

Third, the study replicated and extended the 2013 cardiac arrest findings. DMT levels in the brain increased significantly during cardiac arrest, reaching concentrations comparable to those of serotonin and dopamine, neurotransmitters with well-established functional roles. This concentration comparison is important: it suggests that endogenous DMT reaches levels sufficient to activate neural receptors, at least during the extreme conditions of cardiac arrest.

The Dean et al. study did not resolve all questions. It used rats, not humans. The cardiac arrest condition is extreme and may not represent normal physiological DMT production. And the relationship between pineal DMT content and pineal DMT production (the gland might accumulate DMT produced elsewhere rather than synthesizing it in situ) requires further investigation. Nevertheless, the study represents the strongest evidence to date supporting Strassman's original hypothesis.

Endogenous DMT Levels: How Much Do We Naturally Produce?

A persistent question in DMT research concerns whether the human body produces enough DMT endogenously to affect consciousness under normal conditions (not just during cardiac arrest). The answer depends on understanding the difference between circulating concentrations and local tissue concentrations.

DMT has been detected in human blood at concentrations of approximately 0.05-0.2 nanograms per millilitre. During Strassman's exogenous DMT experiments, peak blood concentrations reached roughly 30-100 nanograms per millilitre, roughly 500-2,000 times higher than endogenous levels. At first glance, this enormous difference suggests that endogenous DMT cannot produce experiential effects.

However, this reasoning makes a critical assumption: that blood concentrations accurately represent concentrations at the sites of action. In neuropharmacology, this assumption is often wrong. Many neurotransmitters operate at local synaptic concentrations vastly higher than their blood levels. Serotonin, for example, reaches millimolar concentrations in synaptic clefts while maintaining nanomolar concentrations in blood. If DMT functions as a local neurotransmitter rather than a circulating hormone, its effective concentration at pineal receptor sites could be orders of magnitude higher than blood measurements indicate.

The Dean et al. finding that brain tissue DMT concentrations during cardiac arrest approach those of serotonin and dopamine supports this possibility. If the pineal gland produces DMT at concentrations comparable to established neurotransmitters, the endogenous production hypothesis becomes biochemically plausible even for non-extreme conditions. The question shifts from "does the body produce enough DMT?" to "under what conditions does local DMT production reach functionally significant concentrations?"

Proposed answers include: during REM sleep (when the pineal is active and melatonin production peaks), during extended meditation (when altered breathing patterns and reduced sensory input may facilitate pineal activity), during birth (when massive hormonal shifts could trigger unusual biosynthetic activity), and during periods of extreme physical or emotional stress (when catecholamine release could cross-activate tryptamine pathways).

What Triggers Endogenous DMT Release?

If the pineal gland does produce DMT, understanding what triggers its release becomes a question of practical significance for consciousness researchers and practitioners alike.

Cardiac arrest and near-death. The Dean et al. study provided direct evidence for this trigger. The mechanism likely involves the cascade of neurochemical events during brain hypoxia: as oxygen supply drops, normal neural inhibition weakens, and biosynthetic pathways may shift from their normal products toward stress-response molecules. The near-death experience literature describes consistent phenomenological features (tunnel of light, life review, encounters with deceased relatives, overwhelming love and peace) that overlap with DMT experiences in several respects.

REM sleep and dreaming. The pineal gland's production of melatonin is directly linked to sleep architecture, and the biochemical pathways for melatonin and DMT production share common precursors and enzymes. During REM sleep, when dreaming is most vivid, the pineal is actively producing melatonin and could theoretically co-produce DMT. The phenomenological overlap between dreams and DMT experiences (vivid imagery, narrative content, entity encounters, altered physics) supports this connection. The "dark retreat" tradition in Tibetan Buddhism, where practitioners spend three or more days in complete darkness, reportedly produces increasingly vivid visions that practitioners and researchers have likened to DMT experiences, possibly through enhanced pineal activity in the absence of light.

Meditation and breathwork. Advanced meditation practices, particularly those involving sustained breath retention, rhythmic breathing, or intense concentration on the third eye region, produce altered states with some DMT-like features. The pranayama tradition describes specific techniques believed to activate the ajna chakra (the energy centre corresponding to the pineal gland). If the pineal gland's piezoelectric crystals respond to pressure changes in the cerebrospinal fluid (which breathwork certainly produces), this could provide a mechanical trigger for DMT release.

Electromagnetic exposure. The pineal gland's piezoelectric calcite microcrystals (documented by Baconnier et al. in 2002) generate electrical voltages in response to mechanical stress and conversely change shape in response to electrical fields. This bidirectional electromagnetic sensitivity means the pineal gland could theoretically respond to environmental electromagnetic fields, including geomagnetic field fluctuations, solar activity, and artificially generated fields. Michael Persinger's research at Laurentian University used weak, complex electromagnetic fields applied to the temporal lobes to produce experiences with some features overlapping both mystical experiences and DMT states, though his specific findings and methodology have been debated.

The Melatonin-DMT Connection in Pineal Biochemistry

The biochemical relationship between melatonin and DMT production in the pineal gland deserves detailed attention because it suggests that conditions favouring melatonin production may simultaneously favour DMT production.

Both melatonin and DMT derive from the same starting material: the amino acid tryptophan. The pineal gland converts tryptophan to serotonin (via 5-hydroxytryptophan), then converts serotonin to melatonin through two steps: N-acetylation by AANAT (arylalkylamine N-acetyltransferase) and O-methylation by HIOMT (hydroxyindole-O-methyltransferase). DMT synthesis branches from an earlier point: tryptophan is decarboxylated to tryptamine by AADC, then N-methylated to DMT by INMT.

These pathways compete for the same precursor (tryptophan) and operate within the same cellular environment. Factors that increase the pineal's overall tryptamine processing capacity, such as darkness (which activates the entire pineal biosynthetic apparatus), tryptophan-rich diet, and adequate cofactors (B6, B12, folate, SAMe), could theoretically increase both melatonin and DMT production simultaneously.

The inverse is also significant. Factors that suppress pineal function, including chronic light exposure at night (screens, LED lighting), fluoride accumulation, and calcification, would theoretically reduce both melatonin and DMT production. This provides a mechanistic basis for the observation that modern lifestyles (constant artificial light, fluoridated water, limited darkness) may diminish the pineal's capacity for both sleep regulation and consciousness-modifying functions.

Melatonin's own consciousness-modifying effects are well established. High-dose melatonin produces vivid dreams, and supplemental melatonin reliably increases dream recall and dream vividness. If melatonin and DMT production are linked, the dream-enhancing effects of melatonin may partly reflect co-produced DMT rather than melatonin alone. This would explain why melatonin's dream effects (vivid, sometimes bizarre imagery with occasional entity-like figures) share features with low-dose DMT experiences.

Fluoride, Calcification, and the Declining Pineal

Jennifer Luke's 2001 doctoral research at the University of Surrey established a fact with profound implications for pineal DMT research: the human pineal gland accumulates fluoride at higher concentrations than any other soft tissue in the body.

Luke examined pineal glands from human cadavers and found fluoride concentrations averaging approximately 9,000 ppm (parts per million). For comparison, bone tissue, long recognized as the body's primary fluoride reservoir, contains approximately 2,500 ppm. Other soft tissues contain negligible fluoride. The pineal gland's preferential fluoride accumulation appears connected to its unique vascular supply and its tendency to calcify, creating hydroxyapatite crystals that incorporate fluoride into their crystal structure.

Pineal calcification begins in childhood and progresses throughout life. By age 17, significant calcification is visible on head X-rays in most individuals. By middle age, the pineal gland is often the most readily identifiable structure on radiological imaging precisely because of its calcification. The progressive replacement of functional pineal tissue with calcified deposits reduces the gland's biosynthetic capacity for both melatonin and, potentially, DMT.

This progressive calcification correlates with several observations from both scientific and spiritual traditions. Melatonin production peaks in childhood and declines steadily with age, paralleling pineal calcification. Children's sleep architecture includes proportionally more REM sleep (when endogenous DMT might be produced) than adult sleep. Spiritual traditions across cultures describe children as having greater access to non-ordinary perception (seeing auras, having imaginary friends, perceiving "invisible" presences) that diminishes with maturation. Rudolf Steiner's educational philosophy specifically addresses this transition, describing how children's natural clairvoyance recedes as physical development progresses.

Strategies for supporting pineal health and potentially reducing calcification have attracted significant interest. These include minimizing fluoride exposure (using filtered water that removes fluoride, choosing fluoride-free dental products), consuming foods reported to support pineal decalcification (raw cacao, turmeric/curcumin, chlorella and spirulina, apple cider vinegar, iodine-rich foods), maintaining natural light-dark cycles (avoiding screens before sleep, sleeping in complete darkness), and regular meditation practice with focus on the third eye region.

Extended-State DMT: The Gallimore-Strassman Infusion Protocol

One of the most exciting developments in DMT research is the extended-state DMT concept developed by Andrew Gallimore, a computational neurochemist at the Okinawa Institute of Science and Technology, in collaboration with Rick Strassman. Their 2016 paper in Frontiers in Pharmacology presented a pharmacokinetic model for maintaining stable DMT blood levels through continuous intravenous infusion.

The fundamental challenge with smoked or injected DMT is its brevity. The experience peaks within 2-5 minutes and resolves within 15-20 minutes because the enzyme monoamine oxidase (MAO) rapidly degrades DMT in the blood and brain. This brevity makes the experience overwhelming and difficult to navigate: by the time the subject orients to the DMT space, the experience is already fading. Extended infusion would solve this by continuously replacing the DMT that MAO degrades, maintaining a stable concentration at receptor sites.

Gallimore's pharmacokinetic model, based on DMT's known distribution and metabolism rates, calculates the infusion rates needed to achieve and maintain target blood concentrations. The model draws on anaesthesiology's target-controlled infusion (TCI) technology, which routinely maintains precise drug concentrations for surgical procedures lasting hours. The technical infrastructure for extended DMT infusion already exists; the primary barriers are regulatory (obtaining approval for such studies) and ethical (ensuring adequate preparation and monitoring for subjects experiencing hours of DMT space).

The research potential of extended-state DMT is enormous. A stable, navigable DMT state would allow systematic phenomenological mapping: What is the DMT space's structure? Are entity encounters reproducible? Can specific "locations" within the space be revisited? Can information received during DMT states be verified? These questions are nearly impossible to address during 15-minute experiences but become approachable during stable, hours-long sessions. Several research groups are reportedly developing protocols based on the Gallimore-Strassman model.

ORMUS, Monatomic Gold, and Pineal Gland Function

The intersection of pineal gland research and ORMUS (Orbitally Rearranged Monoatomic Elements) represents a frontier where two lines of consciousness research converge. While no study has directly investigated how ORMUS materials interact with the pineal gland, several theoretical connections and consistent practitioner reports warrant attention.

The most commonly reported early effect of monatomic gold supplementation is enhanced dream vividness. This effect, reported within the first one to two weeks by a majority of new ORMUS users, directly implicates pineal function. Dreams occur during REM sleep, which the pineal gland regulates through melatonin production. If ORMUS affects the pineal gland (through its piezoelectric crystals, its biosynthetic pathways, or its electromagnetic properties), enhanced dreaming would be an expected early sign.

The pineal gland's piezoelectric calcite microcrystals provide a plausible mechanism for ORMUS-pineal interaction. Piezoelectric materials convert between mechanical and electrical energy. If monoatomic elements exhibit the electromagnetic properties David Hudson described (including Meissner-field effects), their introduction into a biological system containing piezoelectric crystals could create electromagnetic interactions at the nanoscale. The pineal gland, with its documented piezoelectric crystals and its position at the brain's geometric centre, is the most likely site for such interactions.

The ancient tradition of gold-based consciousness preparations (Egyptian mfkzt, Ayurvedic swarna bhasma, Chinese golden elixir) consistently associates gold supplementation with enhanced spiritual perception, a function traditionally attributed to the pineal gland or "third eye." If these ancient practices represented empirical (experience-based) discovery of monatomic gold's effects on pineal function, they constitute thousands of years of observational data supporting the ORMUS-pineal connection.

Modern ORMUS products like NOVA Dead Sea Salt ORMUS provide mineral-rich preparations that can be explored alongside practices known to support pineal health (meditation, darkness exposure, fluoride reduction). The combination of mineral supplementation with consciousness practice may produce effects greater than either approach alone, though this synergy remains a practitioner observation rather than a scientifically verified phenomenon.

The research trajectory is clear even if the destination remains uncertain. Strassman's 2001 hypothesis has been partially confirmed by the 2013 and 2019 studies. Endogenous DMT production in the pineal gland is now established in rats and strongly implied in humans. The extended-state DMT protocol promises to make the DMT state systematically explorable for the first time. And the ORMUS-pineal connection, while still theoretical, provides a framework for understanding why consciousness practitioners across millennia have sought to influence pineal function through mineral supplementation, dietary practices, and meditation techniques that target the "single eye" at the centre of the brain.